Comment
doi: 10.1038/s41585-020-0360-6.
Targeting DNA repair defects in prostate cancer
Affiliations
- PMID: 32651483
- DOI: 10.1038/s41585-020-0360-6
Item in Clipboard
Comment
Targeting DNA repair defects in prostate cancer
Nat Rev Urol.
2020 Aug.
No abstract available
Comment on
-
Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28. N Engl J Med. 2020. PMID: 32343890 Clinical Trial.
Similar articles
-
Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6. Curr Oncol Rep. 2019. PMID: 30919167 Review.
-
DNA damage response and prostate cancer: defects, regulation and therapeutic implications.Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238. Epub 2014 Aug 18. Oncogene. 2015. PMID: 25132269 Free PMC article. Review.
-
Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer.Adv Exp Med Biol. 2019;1210:279-300. doi: 10.1007/978-3-030-32656-2_12. Adv Exp Med Biol. 2019. PMID: 31900913 Review.
-
Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.Future Oncol. 2020 Feb;16(5):75-80. doi: 10.2217/fon-2019-0745. Epub 2020 Jan 9. Future Oncol. 2020. PMID: 31916449 No abstract available.
-
DNA repair genes: contributions to prostate cancer predisposition and aggressiveness.Can J Urol. 2019 Oct;26(5 Suppl 2):10-11. Can J Urol. 2019. PMID: 31629416
Cited by
-
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.Cancer Med. 2021 Aug;10(16):5574-5588. doi: 10.1002/cam4.4113. Epub 2021 Jul 9. Cancer Med. 2021. PMID: 34240817 Free PMC article.
-
Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications.Cells. 2023 May 12;12(10):1375. doi: 10.3390/cells12101375. Cells. 2023. PMID: 37408208 Free PMC article. Review.
-
BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.JCO Precis Oncol. 2022 Jul;6:e2200091. doi: 10.1200/PO.22.00091. JCO Precis Oncol. 2022. PMID: 35834759 Free PMC article. No abstract available.
-
Multi-Omics Analysis Reveals Clinical Value and Possible Mechanisms of ATAD1 Down-Regulation in Human Prostate Adenocarcinoma.Life (Basel). 2022 Oct 30;12(11):1742. doi: 10.3390/life12111742. Life (Basel). 2022. PMID: 36362897 Free PMC article.
References
Original article
-
- de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091–2102 (2020) - DOI
Related articles
-
- Ku, S.-Y. et al. Towards precision oncology in advanced prostate cancer. Nat. Rev. Urol. 16, 645–654 (2019) - DOI
-
- Antonarakis, E. S. Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one? Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-020-0395-x (2020) - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
